Affordable Access

deepdyve-link
Publisher Website

Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups

Authors
  • Fisher, Christine R.1
  • Lowe, David E.2
  • Smith, Todd G.2
  • Yang, Yong2
  • Hutson, Christina L.2
  • Wirblich, Christoph1
  • Cingolani, Gino3
  • Schnell, Matthias J.1, 4
  • 1 Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA
  • 2 National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, USA
  • 3 Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
  • 4 Jefferson Vaccine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Type
Published Article
Journal
Cell Reports
Publisher
Elsevier
Publication Date
Jul 21, 2020
Volume
32
Issue
3
Pages
107920–107920
Identifiers
DOI: 10.1016/j.celrep.2020.107920
PMID: 32697993
PMCID: PMC7373069
Source
PubMed Central
Keywords
License
Unknown

Abstract

Rabies-related viruses cause a similar disease as rabies virus, but protection is not always induced by current vaccines. Fisher et al. design a vaccine featuring a functional, chimeric envelope protein that combines parts of two highly divergent viruses. The vaccine generates robust immune responses and protects against disease in mice.

Report this publication

Statistics

Seen <100 times